Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of V3G CH848 Pr-NP1 and V3G CH848 mRNA-Tr2 HIV Vaccines in Adults Without HIV
NCT05903339Phase 1Active, not recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2023
- Primary completion
- Dec 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1 trial of V3G CH848 Pr-NP1 and V3G CH848 mRNA-Tr2 in human immunodeficiency virus infection (HIV) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Local reactogenicity signs and symptoms at 14 days, Systemic reactogenicity signs and symptoms at 14 days and 5 more. Started Aug 2023; status: active, not recruiting.
02
Drugs
V3G CH848 Pr-NP1V3G CH848 mRNA-Tr2
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05903339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05903339.